Savara Inc (NASDAQ:SVRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Savara Inc (NASDAQ:SVRA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.17.

SVRA has been the topic of a number of analyst reports. JMP Securities reiterated a "market outperform" rating and set a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. HC Wainwright reduced their target price on Savara from $10.00 to $6.00 and set a "buy" rating for the company in a report on Wednesday, November 13th. Finally, Evercore ISI reissued an "in-line" rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday, November 13th.

Insider Buying and Selling at Savara

In related news, Director Joseph S. Mccracken bought 20,000 shares of the business's stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average cost of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the transaction, the director now owns 210,837 shares of the company's stock, valued at approximately $621,969.15. The trade was a 10.48 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.13% of the company's stock.

Institutional Investors Weigh In On Savara

A number of large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its stake in shares of Savara by 9.0% during the third quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company's stock worth $191,000 after acquiring an additional 3,706 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Savara by 15.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company's stock worth $168,000 after purchasing an additional 4,625 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Savara by 14.9% in the second quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company's stock worth $166,000 after purchasing an additional 5,335 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Savara by 5.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company's stock worth $533,000 after purchasing an additional 6,141 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in Savara by 64.4% during the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company's stock valued at $72,000 after buying an additional 6,973 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

Savara Stock Performance

NASDAQ SVRA traded up $0.12 on Friday, hitting $3.72. 2,139,982 shares of the stock traded hands, compared to its average volume of 1,985,028. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The business's fifty day moving average is $3.58 and its two-hundred day moving average is $4.04. Savara has a 12 month low of $2.82 and a 12 month high of $5.70. The firm has a market capitalization of $638.43 million, a price-to-earnings ratio of -8.65 and a beta of 0.92.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). As a group, equities analysts anticipate that Savara will post -0.45 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.